The Banner study will look at whether currently healthy subjects, who are at high risk for Alzheimer’s, might benefit from an amyloid-inhibiting therapy to tackle the disease prior to the onset of symptoms. Read the details of this potentially ground-breaking study, that is tied to a pending examination of certain inhabitants of Colombia who have an uncharacteristic predisposition to Alzheimer’s, here. Gary Marchant, Faculty Director of the Center for Law, Science & Innovation and Regents’ Professor of Law at ASU’s Sandra Day O’Connor College of Law, serves on the Ethics Committee of the Banner study.